(Q37801220)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Silvio Monfardini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Pierre-Louis Soubeyran

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

M Aapro

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

C Bernard-Marty

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

E G C Brain

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

G Batist

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

F Erdkamp

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

K Krzemieniecki

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

R Leonard

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

M Ryberg

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

U Wedding

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

publication date

18 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

257-267

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20956616%20AND%20SRC:MED&resulttype=core&format=json

Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk

15 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Cancer and aging. An evolving panorama

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Understanding and preventing drug interactions in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Undertreatment strongly decreases prognosis of breast cancer in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

The cancer survival gap between elderly and middle-aged patients in Europe is widening

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Acute doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Cardiovascular toxicity caused by cancer treatment: strategies for early detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Detection and monitoring of cardiotoxicity-what does modern cardiology offer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Estimates of the cancer incidence and mortality in Europe in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Effect of screening and adjuvant therapy on mortality from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Adjuvant chemotherapy in older women with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Treatment for anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Lymphoma in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ609